1. Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles
- Author
-
Yusuf Dolen, Carl G. Figdor, Maria Camilla Operti, Eric A. W. van Dinther, Oya Tagit, and Jibbe Keulen
- Subjects
Materials science ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Microfluidics ,microfluidics ,lcsh:RS1-441 ,Pharmaceutical Science ,Nanoparticle ,Nanotechnology ,macromolecular substances ,02 engineering and technology ,010402 general chemistry ,01 natural sciences ,Article ,lcsh:Pharmacy and materia medica ,drug delivery systems ,chemistry.chemical_compound ,All institutes and research themes of the Radboud University Medical Center ,In vivo ,microparticles ,Range (particle radiation) ,technology, industry, and agriculture ,PLGA ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,chemistry ,Drug delivery ,Particle ,nanoparticles ,Particle size ,0210 nano-technology ,biomaterials - Abstract
Polymeric particles made up of biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA) are promising tools for several biomedical applications including drug delivery. Particular emphasis is placed on the size and surface functionality of these systems as they are regarded as the main protagonists in dictating the particle behavior in vitro and in vivo. Current methods of manufacturing polymeric drug carriers offer a wide range of achievable particle sizes, however, they are unlikely to accurately control the size while maintaining the same production method and particle uniformity, as well as final production yield. Microfluidics technology has emerged as an efficient tool to manufacture particles in a highly controllable manner. Here, we report on tuning the size of PLGA particles at diameters ranging from sub-micron to microns using a single microfluidics device, and demonstrate how particle size influences the release characteristics, cellular uptake and in vivo clearance of these particles. Highly controlled production of PLGA particles with ~100 nm, ~200 nm, and >, 1000 nm diameter is achieved through modification of flow and formulation parameters. Efficiency of particle uptake by dendritic cells and myeloid-derived suppressor cells isolated from mice is strongly correlated with particle size and is most efficient for ~100 nm particles. Particles systemically administered to mice mainly accumulate in liver and ~100 nm particles are cleared slower. Our study shows the direct relation between particle size varied through microfluidics and the pharmacokinetics behavior of particles, which provides a further step towards the establishment of a customizable production process to generate tailor-made nanomedicines.
- Published
- 2019
- Full Text
- View/download PDF